1365-2249/asset/cei_left.gif?v=1&s=ffee144c532fe5e73bbb89290ba14e154b0d400b)
1365-2249/asset/cei_right.gif?v=1&s=c14d545a5215173707c8202758d5b25fd0bede44)
Original Article
You have free access to this content
Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease
Article first published online: 3 DEC 2012
DOI: 10.1111/j.1365-2249.2012.04674.x
© 2012 British Society for Immunology
Additional Information
How to Cite
Marzano, A. V., Tedeschi, A., Polloni, I., Crosti, C. and Cugno, M. (2013), Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clinical & Experimental Immunology, 171: 76–81. doi: 10.1111/j.1365-2249.2012.04674.x
Publication History
- Issue published online: 3 DEC 2012
- Article first published online: 3 DEC 2012
- Accepted manuscript online: 26 SEP 2012 02:45AM EST
- Manuscript Accepted: 13 SEP 2012
References
- 1. The pathophysiology of autoimmune blistering diseases. J Clin Invest 2005; 115:825–828.
- 2, , , , , . High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134:465–469.
- 3, , , . What's new in bullous pemphigoid. J Dermatol 2010; 37:194–204.
- 4, , et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol 2009; 160:266–272.
- 5
- 6, , . T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116:1159–1166.
- 7, , , , , . Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 2004; 137:595–600.
- 8, , , , , . Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol 1998; 138:611–614.Direct Link:
- 9, , , , , . Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 2009; 158:31–36.
- 10, , , , . Skin autoimmunity and blood coagulation. Autoimmunity 2010; 43:189–194.
- 11, , , . Activation of blood coagulation in autoimmune skin disorders. Exp Rev Clin Immunol 2009; 5:605–613.
- 12, , , , , . Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 2011; 165:44–50.
- 13, , et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141:691–698.
- 14, , , . Increased risk of stroke in patients with bullous pemphigoid: a population-based follow-up study. Stroke 2011; 42:319–323.
- 15, , . Venous thrombosis in the elderly. J Thromb Haemost 2007; 5 (Suppl. 1):310–317.
- 16, , et al. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009; 37:424–431.
- 17, , et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006; 4:1510–1516.
- 18, , , , , . Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010; 28:254–257.
- 19, , . Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid. Acta Derm Venereol 1989; 69:527–529.
- 20, , . An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Clin Exp Dermatol 1993; 18:119–123.
- 21, . The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. J Clin Invest 1993; 92:978–983.
- 22, , , , , . Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin Exp Immunol 2004; 135:497–504.
- 23, , , , , . Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115:879–887.
- 24, , et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Haemost 2005; 3:280–286.
- 25. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5 (Suppl 1):132–142.
- 26, , , , , . Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol 2007; 57:397–400.
- 27, , et al. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. J Clin Endocrinol Metab 2012; 97:1463–1473.
- 28, , , . Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49:1071–1080.
- 29, , et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66:479–485.
- 30, , , . Topical class I corticosteroids in 10 patients with bullous pemphigoid: correlation of the outcome with the severity degree of the disease and review of the literature. J Eur Acad Dermatol Venereol 2004; 18:164–168.
- 31, , et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144:41–48.
- 32, , , . Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012; 30:3–16.
- 33, , . Serological studies in bullous pemphigoid: a literature review of antibody titers at presentation and in clinical remission. Acta Derm Venereol 2010; 90:115–121.
- 34, , et al., Gruppo Ligure di Studi in Dermatologia (GLISID). Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol 2001; 15:317–319.